Aykan, M. B. Et Al. 2025. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium. Therapeutic Advances in Medical Oncology , vol.17 .

Aykan, M. B., BÖLEK, H., YEKEDÜZ, E., Sertesen, E., Tural, D., Karaçin, C., ... ŞENDUR, M. A. N.(2025). Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium. Therapeutic Advances in Medical Oncology , vol.17.

Aykan, Musa Et Al. "Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium," Therapeutic Advances in Medical Oncology , vol.17, 2025

Aykan, Musa B. Et Al. "Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium." Therapeutic Advances in Medical Oncology , vol.17, 2025

Aykan, M. B. Et Al. (2025) . "Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium." Therapeutic Advances in Medical Oncology , vol.17.

@article{article, author={Musa Barış Aykan Et Al. }, title={Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium}, journal={Therapeutic Advances in Medical Oncology}, year=2025}